Shanghai Bio-heart (HKG:2185) has launched its new Iberis device for kidney nerve treatment at the Oriental Congress of Cardiology 2025, according to a Tuesday filing.
Developed by its unit AngioCare, the device is the first globally approved for both transradial and transfemoral access.
The treatment will be jointly promoted in China by AngioCare and CardioNavi, a unit of Grand Pharmaceutical (HKG:0512), the filing said.
Shares of the medical device maker rose about 7% by Wednesday's close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.